- Home
- GNSS vs ATOS Comparison
GNSS vs ATOS Comparison
Compare GNSS & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNSS
- ATOS
- Stock Information
- Founded
- GNSS 1992
- ATOS 2009
- Country
- GNSS United States
- ATOS United States
- Employees
- GNSS N/A
- ATOS N/A
- Industry
- GNSS Consumer Electronics/Appliances
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- GNSS Consumer Staples
- ATOS Health Care
- Exchange
- GNSS Nasdaq
- ATOS Nasdaq
- Market Cap
- GNSS 116.8M
- ATOS 113.7M
- IPO Year
- GNSS N/A
- ATOS 2012
- Fundamental
- Price
- GNSS $2.71
- ATOS $0.86
- Analyst Decision
- GNSS Strong Buy
- ATOS Strong Buy
- Analyst Count
- GNSS 3
- ATOS 3
- Target Price
- GNSS $5.33
- ATOS $7.00
- AVG Volume (30 Days)
- GNSS 182.0K
- ATOS 928.8K
- Earning Date
- GNSS 02-11-2025
- ATOS 11-12-2024
- Dividend Yield
- GNSS N/A
- ATOS N/A
- EPS Growth
- GNSS N/A
- ATOS N/A
- EPS
- GNSS N/A
- ATOS N/A
- Revenue
- GNSS $24,008,000.00
- ATOS N/A
- Revenue This Year
- GNSS $136.42
- ATOS N/A
- Revenue Next Year
- GNSS $56.53
- ATOS N/A
- P/E Ratio
- GNSS N/A
- ATOS N/A
- Revenue Growth
- GNSS N/A
- ATOS N/A
- 52 Week Low
- GNSS $1.51
- ATOS $0.77
- 52 Week High
- GNSS $4.04
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- GNSS 38.98
- ATOS 31.05
- Support Level
- GNSS $2.57
- ATOS $0.86
- Resistance Level
- GNSS $2.81
- ATOS $0.94
- Average True Range (ATR)
- GNSS 0.17
- ATOS 0.06
- MACD
- GNSS 0.04
- ATOS -0.00
- Stochastic Oscillator
- GNSS 33.33
- ATOS 4.59
About GNSS Genasys Inc.
Genasys Inc is a provider of Protective Communication solutions, including Genasys Protect software platform and Long Range Acoustic Device (LRAD). Its software platform receives information from variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations. The Company operates in two business segments: Hardware and Software and its markets are North and South America, Europe, Middle East and Asia. Key revenue is generated from Hardware.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.